HC Wainwright Issues Pessimistic Estimate for SRTS Earnings

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Equities researchers at HC Wainwright dropped their Q2 2025 earnings per share estimates for shares of Sensus Healthcare in a research report issued to clients and investors on Monday, February 10th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of $0.07 per share for the quarter, down from their prior estimate of $0.10. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.71 per share. HC Wainwright also issued estimates for Sensus Healthcare’s FY2025 earnings at $0.44 EPS.

A number of other equities analysts also recently weighed in on the company. Maxim Group boosted their target price on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Lake Street Capital started coverage on Sensus Healthcare in a research note on Friday, January 31st. They issued a “buy” rating and a $18.00 target price on the stock.

Sensus Healthcare Stock Performance

Shares of SRTS opened at $5.50 on Wednesday. The stock has a 50 day moving average price of $7.22 and a two-hundred day moving average price of $6.88. The firm has a market capitalization of $90.15 million, a P/E ratio of 13.75 and a beta of 1.24. Sensus Healthcare has a 52 week low of $2.91 and a 52 week high of $9.33.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%.

Hedge Funds Weigh In On Sensus Healthcare

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC lifted its stake in Sensus Healthcare by 5.3% in the fourth quarter. Renaissance Technologies LLC now owns 430,934 shares of the company’s stock valued at $2,982,000 after purchasing an additional 21,600 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Sensus Healthcare by 81.2% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company’s stock valued at $1,039,000 after purchasing an additional 67,269 shares during the last quarter. Geode Capital Management LLC lifted its stake in Sensus Healthcare by 8.5% in the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after purchasing an additional 11,525 shares during the last quarter. Marshall Wace LLP lifted its stake in Sensus Healthcare by 99.6% in the fourth quarter. Marshall Wace LLP now owns 132,286 shares of the company’s stock valued at $915,000 after purchasing an additional 65,994 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC lifted its stake in Sensus Healthcare by 65.1% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 93,248 shares of the company’s stock valued at $645,000 after purchasing an additional 36,785 shares during the last quarter. Hedge funds and other institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.